L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression

International Journal of Gynecological Cancer

Volumn 24, Issue 4, 2014, Pages 659-663

  Watanabe, Jun ^a   Yokoyama, Yoshihito ^b   Futagami, Masayuki ^b   Mizunuma, Hideki ^b   Yoshioka, Haruhiko ^a   Washiya, Kiyotada ^a   Hana, Kiyomi ^c   Endou, Hitoshi ^d   Okayasu, Isao ^c  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endometrial endometrioid adenocarcinoma; Histological grade; LAT1; P53

Indexed keywords

AMINO ACID TRANSPORTER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; L TYPE AMINO ACID TRANSPORTER 1; PROGESTERONE RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CELL MEMBRANE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM ATROPHY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MODERATELY DIFFERENTIATED ENDOMETRIAL ENDOMETRIOID CARCINOMA; POORLY DIFFERENTIATED ENDOMETRIAL ENDOMETRIOID CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; WELL DIFFERENTIATED ENDOMETRIAL ENDOMETRIOID CARCINOMA; ADENOCARCINOMA; AGED; CANCER GRADING; COMPARATIVE STUDY; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84900436147     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000123     Document Type: Article

References (23)

1. A report of gynecologic oncology committee of Japan. Acta Obstet Gynecol Jpn. 2012;64:2354-2365.
2. Hata H, Hamano M, Watanabe J, et al. Role of estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells. Oncology. 1998;55: 35-44.
3. Watanabe J, Kamata Y, Seo N, et al. Stimulatory effect of estrogen on the growth of endometrial cancer cells is regulated by cell-cycle regulators. J Steroid Biochem Mol Biol. 2007; 107:163-171.
4. Kamata Y, Watanabe J, Hata H, et al. Quantitative study on the correlation between p53 gene mutation and its expression in endometrial carcinoma cell lines. Eur J Gynaecol Oncol. 2003; 25:55-60.
5. Watanabe J, Kamata Y, Kanai T, et al. Expression of cell cycle regulators in endometrial adenocarcinoma. In: Kuramoto H Nishida M, eds. Cell and Molecular Biology of Endometrial Carcinoma. Tokyo, Japan: Springer; 2003:93-106.
6. Miyamoto T, Watanabe J, Hata H, et al. Significance of progesterone receptor-A and-B expressions in endometrial adenocarcinoma. J Seroid Biochem Mol Biol. 2004;92:111-118.
7. Watanabe J, Nishimura Y, Tsunoda S, et al. Liquid-based preparation for endometrial cytologyVusefulness for predicting the prognosis of endometrial carcinoma preoperatively. Cancer. 2009;117:254-263.
8. Kanai Y, Segawa H, Miyamoto K, et al. Expression cloning and characterization of a transporter large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998; 273:23629-23632.
9. Nakata N, Mikami T, Hana K, et al. Unique and selective expression of L-amino acid transporter inhuman tissues as well as being an aspect of oncofetal protein. Histol Histopathol. 2013;29:217-227.
10. SakataT, FerdousG,TsurutaT, et al.L-type amino acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7-18.
11. Furuya M, Horiguchi J, Nakajima H, et al. Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci. 2012;103:382-389.
12. Kobayashi H, IshiiY, Takayama T. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol. 2005;90:233-238.
13. Kaira K, Oriuchi N, Imai H, et al. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage 1 pulmonary adenocarcinoma. Lung Cancer. 2009;66:120-126.
14. Ichinoe M, Mikami T, Yoshida T, et al. High expression of L-type amino acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 2011;61:281-289.
15. Yanagisawa N, Ichinoe M, Mikami T, et al. High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinoma. J Clin Pathol. 2012;0:1-5.
16. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103-104
17. Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res. 1995; 55:237-241.
18. Wang Q, Bailey CG, Ng C, et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 2011;71:7525-7536.
19. Wang Q, Tiffen J, Baily CG, et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst. 2013;105:1463-1473.
20. FukuharaD, KanaiY,Chairoungdua A, et al. Protein characterization of Na-independent system L amino acid transporter 3 in mice. A potential role in supply of branched-chain amino acids under nutrient starvation. Am J Pathol. 2007;170:888-898.
21. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis andKi-67, p53, and p21 expression: a population-based endometrial carcinoma study. J Clin Oncol. 1999;17:1382-1390.
22. Oda K, Hosoda N, Endo H, et al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer sci. 2009;101:173-179.
23. Shennan DB, Thomson J. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep. 2008;20:885-889.